BioHarvest Sciences Inc. (BHST) Key Metrics
BHST valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $41.9M
- Enterprise value
- $35.7M
- P/E (TTM)
- —
- Forward P/E
- 153.8
- PEG ratio
- —
- Price / sales
- 1.2
- Price / book
- 1.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.38
BHST key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBHST valuation Price multiples at each fiscal year-end price.
Price / sales−30.3%
2.8
2025 · hover or tap a bar for each year
20152025
Price / book−95.0%
3.8
2025 · hover or tap a bar for each year
20152025
Free cash flow yield−0.5 pts
−10.0%
2025 · hover or tap a bar for each year
20152025
BHST returns How much profit the business earns on the capital it uses.
Return on equity
−83.2%
2025 · hover or tap a bar for each year
20152025
Return on invested capital+44.1 pts
−30.1%
2025 · hover or tap a bar for each year
20152025
Return on assets+33.9 pts
−30.6%
2025 · hover or tap a bar for each year
20152025
Free cash flow margin+10.0 pts
−27.8%
2025 · hover or tap a bar for each year
20152025
Asset turnover−24.6%
0.95
2025 · hover or tap a bar for each year
20152025
BHST per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+20.5%
$1.87
2025 · hover or tap a bar for each year
20152025
Earnings per share
−$0.60
2025 · hover or tap a bar for each year
20152025
Free cash flow per share
−$0.52
2025 · hover or tap a bar for each year
20152025
Book value per share+1,582.9%
$1.38
2025 · hover or tap a bar for each year
20152025
Shares outstanding+13.7%
18.4M
2025 · hover or tap a bar for each year
20152025
BHST financial health Debt, liquidity and how easily interest is covered.
Debt / equity−94.7%
0.55
2025 · hover or tap a bar for each year
20152025
Net debt−$20.3M
−$8.9M
2025 · hover or tap a bar for each year
20152025
Current ratio+620.4%
3.97
2025 · hover or tap a bar for each year
20152025
Interest coverage
-2.0
2025 · hover or tap a bar for each year
20152025
Debt / assets−46.5%
0.30
2025 · hover or tap a bar for each year
20152025
BHST efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+2 days
19 days
2025 · hover or tap a bar for each year
20152025
Days of inventory+7 days
107 days
2025 · hover or tap a bar for each year
20152025
Days payables outstanding−6 days
80 days
2025 · hover or tap a bar for each year
20152025
Cash conversion cycle+16 days
46 days
2025 · hover or tap a bar for each year
20152025
Capex / revenue−4.4 pts
6.8%
2025 · hover or tap a bar for each year
20152025
BHST valuation history
Fiscal year-endToday10-year median
BHST returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BHST debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BHST price vs earnings per share
Share price at year-endEPS (right axis)
BHST key metrics
2015–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $95.6M | $100.1M | — | — | — | — | — | — | — | — |
| Enterprise value | $86.6M | $111.5M | — | — | — | — | — | — | — | — |
| Price / sales | 2.8 | 4.0 | — | — | — | — | — | — | — | — |
| Price / book | 3.8 | 75.2 | — | — | — | — | — | — | — | — |
| EV / sales | 2.5 | 4.4 | — | — | — | — | — | — | — | — |
| Earnings yield | −11.7% | −12.9% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −10.0% | −9.5% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $5.19 | $6.18 | — | — | — | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $1.87 | $1.56 | $0.94 | $0.42 | $0.17 | $0.04 | — | — | — | — |
| Earnings per share | −$0.60 | −$0.80 | −$0.93 | −$0.86 | −$0.79 | −$0.68 | — | — | — | — |
| Operating cash flow per share | −$0.39 | −$0.41 | −$0.63 | −$0.71 | −$0.55 | −$0.40 | — | — | — | — |
| Free cash flow per share | −$0.52 | −$0.59 | −$0.74 | −$0.80 | −$0.68 | −$0.42 | — | — | — | — |
| Cash per share | $1.25 | $0.15 | $0.40 | $0.13 | $0.33 | $0.18 | — | — | — | — |
| Book value per share | $1.38 | $0.08 | −$1.10 | −$0.45 | $0.23 | −$0.24 | — | — | — | — |
| Tangible book value per share | $1.38 | $0.08 | −$1.10 | −$0.45 | $0.23 | −$0.24 | — | — | — | — |
| Capex per share | $0.13 | $0.18 | $0.11 | $0.10 | $0.13 | $0.02 | — | — | — | — |
| Debt per share | $0.77 | $0.85 | $1.65 | $0.81 | $0.21 | $0.28 | — | — | — | — |
| Shares outstanding | 18.4M | 16.2M | 13.5M | 13.1M | 12.4M | 9.7M | — | — | — | — |
| Change in shares outstanding | +13.7% | +19.7% | +3.7% | +4.9% | +28.1% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −83.2% | — | — | — | — | — | — | −4.7% | — | −319.6% |
| Return on invested capital (ROIC) | −30.1% | −74.2% | −313.4% | −390.8% | — | — | — | −9.2% | −227.0% | −203.4% |
| Return on assets (ROA) | −30.6% | −64.6% | −103.0% | −114.6% | −126.7% | −179.7% | −457.0% | −2.8% | −153.7% | −169.6% |
| Return on tangible assets | −23.4% | −51.6% | −83.7% | −119.6% | −96.3% | −124.1% | −262.6% | −1.7% | −167.9% | −169.6% |
| Free cash flow margin | −27.8% | −37.8% | −78.9% | −190.9% | −401.2% | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $14.1M | $13.8M | $22.3M | $10.6M | $2.7M | $2.7M | $26.2M | $8,105 | $80,940 | $25,355 |
| Cash & short-term investments | $23.0M | $2.4M | $5.4M | $1.7M | $4.1M | $1.8M | $911,000 | $216,289 | $1,357 | $16,809 |
| Net debt | −$8.9M | $11.4M | $17.0M | $8.8M | −$1.5M | $932,000 | $25.3M | −$208,184 | $79,583 | $8,546 |
| Debt / equity | 0.55 | 10.39 | — | — | 0.93 | — | — | 0.03 | — | 0.65 |
| Debt / assets | 0.30 | 0.55 | 1.49 | 1.12 | 0.26 | 0.51 | 12.97 | 0.03 | 1.31 | 0.35 |
| Current ratio | 3.97 | 0.55 | 0.34 | 0.38 | 1.94 | 1.18 | 0.05 | 7.89 | 0.02 | 0.33 |
| Quick ratio | 3.38 | 0.29 | 0.25 | 0.26 | 1.62 | 1.13 | 0.05 | 7.89 | 0.02 | 0.33 |
| Interest coverage | -2.0 | -3.6 | -5.1 | -7.6 | -10.5 | -11.5 | -1.0 | -1.3 | -14.3 | -56.5 |
| Working capital | $22.8M | −$6.4M | −$17.4M | −$7.2M | $2.7M | $343,000 | −$25.2M | $190,829 | −$118,803 | −$37,865 |
| Invested capital | $16.5M | $12.8M | $2.1M | $2.9M | $1.4M | −$1.4M | −$5.2M | $65,864 | $20,014 | $47,259 |
| Tangible asset value | $25.4M | $1.3M | −$14.9M | −$5.9M | $2.9M | −$2.3M | −$27.0M | $274,048 | −$59,569 | $16,085 |
| Net current asset value | $8.3M | −$15.8M | −$20.8M | −$11.0M | −$1.7M | −$5.4M | −$27.7M | $190,829 | −$118,803 | −$37,865 |
| Graham net-net per share | $0.26 | −$1.14 | −$1.67 | −$0.95 | −$0.19 | −$0.57 | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / revenue | 6.8% | 11.3% | 11.6% | 22.8% | 78.0% | 43.7% | 15.6% | — | — | — |
| Capex / depreciation | 1.45 | 2.27 | 1.75 | 1.76 | 4.25 | 0.60 | 0.10 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 1.7% | 2.4% | 4.4% | 24.6% | 160.2% | 349.2% | 209.2% | — | — | — |
| R&D / revenue | 15.4% | 19.0% | 26.6% | 42.0% | 196.4% | 319.2% | 617.4% | — | — | — |
| SG&A / revenue | 55.5% | 58.2% | 95.3% | 170.1% | 226.4% | 1,089.4% | 422.0% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 19.0 | 16.7 | 24.3 | 44.5 | 84.6 | 292.6 | 237.1 | — | — | — |
| Days of inventory on hand | 106.8 | 99.3 | 99.7 | 98.4 | 131.0 | 106.8 | 98.5 | — | — | — |
| Days payables outstanding | 80.0 | 86.1 | 73.8 | 82.8 | 167.0 | 592.8 | 415.9 | — | 25,604.1 | 21,874.1 |
| Cash conversion cycle (days) | 45.8 | 30.0 | 50.2 | 60.1 | 48.6 | -193.3 | -80.3 | — | — | — |
| Receivables turnover | 19.25 | 21.81 | 15.00 | 8.19 | 4.32 | 1.25 | 1.54 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 4.56 | 4.24 | 4.95 | 4.41 | 2.19 | 0.62 | 0.88 | — | 0.01 | 0.02 |
| Inventory turnover | 3.42 | 3.67 | 3.66 | 3.71 | 2.79 | 3.42 | 3.71 | — | — | — |
| Asset turnover | 0.95 | 1.26 | 1.04 | 0.56 | 0.27 | 0.11 | 0.19 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.8M | $1.2M | $845,000 | $671,000 | $487,000 | $317,500 | $141,620 | $1,626 | $1,062 | $1,110 |
| Average payables | $3.1M | $2.7M | $1.4M | $971,000 | $655,000 | $419,000 | $215,350 | $33,967 | $35,156 | $30,076 |
| Average inventory | $4.1M | $3.1M | $1.9M | $1.2M | $514,000 | $75,500 | $51,000 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BHST's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BHST valuation and financial ratios
BioHarvest Sciences earned a return on equity of −83.2% and a return on invested capital of −30.1% in fiscal 2025. It ended the year with $14.1 million of debt and $23.0 million in cash and short-term investments, a net cash position of $8.9 million.
See the BHST income statement, the BHST chart for price history, or the BHST stock overview for the latest quote and news.
BHST key metrics FAQ
What is BioHarvest Sciences's return on equity?
BioHarvest Sciences's return on equity (ROE) was −83.2% in fiscal 2025: net income of -$11.1 million on average shareholders' equity of $13.4 million.
What is BioHarvest Sciences's ROIC?
BioHarvest Sciences's return on invested capital was −30.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does BioHarvest Sciences have?
BioHarvest Sciences had total debt of $14.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.55 and more cash than debt.
What is BioHarvest Sciences's free cash flow yield?
BioHarvest Sciences generated -$9.6 million of free cash flow in fiscal 2025, a free cash flow yield of −10.0% on its market value at year-end ($95.6 million).
What is BioHarvest Sciences's current ratio?
BioHarvest Sciences's current ratio was 3.97 at the end of fiscal 2025: current assets were 3.97 times current liabilities.